Interní Med. 2001; 3(9): 419-423

Ovlivnění endoteliální dysfunkce a zánětlivých parametrů u nemocných s kombinovanou hyperlipoproteinémií po terapii ciprofibrátem

MUDr. Tomáš Kvasnička1, MUDr. Richard Češka CSc2, doc. MUDr. Jan Kvasnička DrSc1, MUDr. Michal Vrablík2
1 OKH I. interní kliniky VFN a 1. LF UK, Praha
2 III. interní klinika VFN a 1. LF UK, Praha

Keywords: kombinovaná hyperlipoproteinémie, ciprofibrát, cytoadhezivní molekuly, proteiny akutní fáze.

Published: December 31, 2001  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kvasnička T, Češka R, Kvasnička J, Vrablík M. Ovlivnění endoteliální dysfunkce a zánětlivých parametrů u nemocných s kombinovanou hyperlipoproteinémií po terapii ciprofibrátem. Interní Med. 2001;3(9):419-423.

Cílem naší studie bylo sledování rozdílu v lipidových parametrech, hladinách solubilních cytoadhezivních molekul jako markerů endoteliální dysfunkce a dále současné sledování změn hladin proteinů akutní fáze, které odrážejí výši zánětlivé reakce na -systémové- úrovni v plazmě pacientů s diagnózou kombinované hyperlipoproteinémie před a po 3 měsících terapie ciprofibrátem v dávce 100 mg denně. Do studie bylo vybráno celkem 40 nemocných (18 mužů a 22 žen; věk 45 ± 7 let) bez předchozí hypolipidemické terapie, s dietní intervencí posledních 6 týdnů před začátkem terapie (dle AHA I). Nemocní byli bez symptomů kardiovaskulárních onemocnění. Další vylučovací kritéria výběru byla renální insuficience, proteinurie, alterované jaterní testy, nikotinizmus, diabetes mellitus a hypertenze.

III. interní klinika VFN a 1. LF UK, Praha,

OKH I. interní kliniky VFN a 1. LF UK, Praha

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Anderson, P., Smith, P., Seljeflot, I., et. al.: Effects of gemfibrozil on lipids and hemostasis after myocardial infarction. Trombosis and Haemostasis, 63, 1990, s 174-177. Go to original source...
    2. Castelli, W. P.: Epidemiology of triglycerides: a view from Framingham. Am. J. Cardiol., 70, 1992, s. 3H-9H. Go to original source... Go to PubMed...
    3. Austin, M. A., Hokanson, J. E.: Epidemiology of trigly- 5. cerides, small dense low density lipoprotein and lipoprotein/a/ as risk factors for coronary heart disease. Medical Clinics of North America, 1994, 78, s. 99-115. Go to original source... Go to PubMed...
    4. Grundy, S. M.: Small LDL atherogenic dyslipidemia and the metabolic syndrom, Circulation, 1997, 95, s. 1-4. Go to original source... Go to PubMed...
    5. Ross, R. (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature; 362, 801-809. Go to original source... Go to PubMed...
    6. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999, 320: 115-126. Go to original source... Go to PubMed...
    7. Munro JM, Cotran RS. the pathogenesis of atherosclerosis: atherogenesis and inflammation. Lab Invest, 1988, 58: 249-260.
    8. Abe Y, El-Masri B., Kimball K.T., Reilly C.F., Osmundsen K., Smith C.W., Ballantyne C.M.: Soluble Cell Adhesion Molecules in Hypertriglyceridemia and Potential. Singificance on Monocyte Adhesion. Circulation. 1998; 91: 1952-1958.
    9. Hackman A., Abe Y., Insull W. Jr., Pownall H., Smith L., Dunn K., Gotto AM. Jr., Ballantyne CM.: Levels of soluble cell adhesion molecules in patient with dyslipidemia. Circulation, 1996 Apr, 93: 7, 1334-8. Go to original source... Go to PubMed...
    10. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risk of future myocardial infarctionin apparently healthy men. Lancet 1998; 351: 88-92. Go to original source... Go to PubMed...
    11. de Maat MP; Pietersma A; Kofflard M; Sluiter W; Kluft C, Association of plasma fibrinogen levels with coronary artery disease, smoking and inflammatory markers. Atherosclerosis, 1996 Apr, 121: 2, 185-91. Go to original source... Go to PubMed...
    12. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB: Elevated Creactive protein levels in overweight and obese adults. JAMA 1999 Dec 8, 282 (22): 2131-5. Go to original source... Go to PubMed...
    13. Stamper J, et al. (MRFIT): Is relationship between serum cholesterol and risk remature death from coronary heart disease continous and grade? JAMA 1986; 256: 2823-2828. Go to original source...
    14. Friedman GD, Klastsky AL, Siegelaub AB. The leukocyte count as a predictor of myocardial infarction. N Engl J Med. 1974, 290: 1275-1278. Go to original source... Go to PubMed...
    15. Weijemberg MP, Feskens EJM, Kromhout D. White blood cell count and the risk of coronary heart disease and all-cause mortality in elderly men. Arterioscle Thromb Vasc Biol. 1996, 16: 499-503. Go to original source... Go to PubMed...
    16. Blann AD, McCollum ChN, Steiner M: Circulating adhesion molecules in inflammatory and athrosclerotic vascular disease. Immunology Today, 1995, 16: 251-252. Go to original source... Go to PubMed...
    17. Danesh J, Muir J, Wong YK, Ward M, Gallimore JR, Pepys MB Risk factors for coronary hearth disease and acute-phase proteins. A population based study. Eur Hearth J 1999 Jul, 20 (13): 954-9. Go to original source... Go to PubMed...
    18. Blann AD; McCollum CN, Increased levels of soluble tumor necrosis factor receptors in atherosclerosis: no clear relationship with levels of tumor necrosis factor. Inflammation, 1998 Oct, 22: 5, 483-91. Go to original source... Go to PubMed...
    19. Danesh J, Collins R Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary hearth disease: meta-analyses of prospective studies. JAMA 1998; 279: 1477-82. Go to original source... Go to PubMed...
    20. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9. Go to original source... Go to PubMed...
    21. Mantovani, A., Sozzani, S., Vecchi, A., Introna, M. & Allavena P. (1997) Cytokine activation of endothelial cells: new molecules for an old paradigm. Thrombosis and Haemostasis; 78, 406-414. Go to original source... Go to PubMed...
    22. Mantovani, A., Bussolino, F. & Introna M. (1997) Cytokine regulation of endothelial cell function: from molecular level to the bedside. Immunology Today; 18, 231-240. Go to original source... Go to PubMed...
    23. Maruna P., Gürlich R., Mašek Z.: Procalcitonin - an early marker of postoperative sepsis. The comparison with a set of cytokines and soluble receptors. Intensive Care Med. 1998; 22: S139.
    24. Prevention of Coronary Hearth Disease in Clinical Practice. Summary of Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention, 1998.
    25. Sacks F. M., Pfeffer M. A., Moye L. A., et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med., 335, 1996, s. 1001-1009. Go to original source... Go to PubMed...
    26. Frick M. H. et al.: Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle aged men with dyslipidemia. N. Engl. J. Med., 317, 1987, s. 1237-1245. Go to original source... Go to PubMed...
    27. Carlson L. A., Rosenhamer G.: Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med. Scand., 223,1988, s. 405-418. Go to original source... Go to PubMed...
    28. Kvasnička T., Češka R., Haas T. Sledování klinického efektu terapie ciprofibrátem u pacientů s kombinovanou hyperlipoproteinémií. ardiologická Revue 2001; 1: 1-4.
    29. Schoonjans K, Staels B, Auwerx J. Role of peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 1996; 27: 907-25. Go to original source...
    30. Lemberger T, Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Ann Rev Cell Dev Biol 1996; 12: 335-363. Go to original source... Go to PubMed...
    31. Kvasnicka J, Marek J, Kvasnicka T, Weiss V, Markova M, Stepan J, Umlaufova A: Increase of adhesion molecules, fibrinogen, type-1 plasminogen activator inhibitor and orosomucoid in growth hormone (GH) deficient adults and their modulation by recombinant human GH replacement; Clin Endo 52: (5) 543-548 MAY 2000. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.